Parkinson’s disease is a chronic, progressive, neurodegenerative condition that damages central nervous system pathways. In addition to the wellrecognised motor features of the disease, patients commonly experience nonmotor symptoms including neuropsychiatric complications. These symptoms may precede motor symptoms and have a very significant impact on quality of life for patients and their carers.
National Institute for Health and Clinical Excellence. Parkinson’s disease: diagnosis and management in primary and secondary care. London: NICE; 2006.
2.
MiyasakiJMShannonKVoonV Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:996–1002. doi:10.1212/01.wnl.0000215428.46057.3d
3.
MenzaMDobkinRDMarinH A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72:886–92. doi:10.1212/01.wnl.0000336340.89821.b3
4.
MoellentineCRummansTAhlskogJEEffectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neurosci1998; 10:187–93.
5.
WalshKBennettG. Parkinson’s disease and anxiety. Postgrad Med J 2001; 77:89–93. doi:10.1136/pmj.77.904.89
6.
FenelonGMahieuxFHuonR Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 2000; 123:733–45. doi:10.1093/brain/123.4.733
7.
EmreMAarslandDAlbaneseA Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351:2509–18. doi:10.1056/NEJMoa041470
8.
LeroiIBrandtJReichSG Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry 2004; 19:1–8. doi:10.1002/gps.993
9.
PostumaRBLangAEMassicotte-MarquezJ Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006; 66:845–51. doi:10.1212/01.wnl.0000203648.80727.5b
10.
GagnonJFPostumaRBMontplaisirJ. Update on the pharmacology of REM sleep behavior disorder. Neurology 2006; 67:742–7. doi:10.1212/01.wnl.0000233926.47469.73
11.
DhawanVHealyDGPalS Sleep-related problems of Parkinson’s disease. Age Ageing 2006; 35:220–8. doi:10.1093/ageing/afj087
12.
O’SulliVan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs2009; 23:157–70.
13.
WongSHSteigerMJ.Pathological gambling in Parkinson’s disease. BMJ 2007; 334:810–1. doi:10.1136/bmj.39176.363958.80
14.
KlosKJBowerJHJosephsKA Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophy. Parkinsonism Relat Disord 2005; 11:381–6. doi:10.1016/j.parkreldis.2005.06.005
